Calypso Medical Technologies has received FDA clearance for its Calypso System, a technology that automates response to organ motion occurring during radiation delivery to prostate cancer tumors. 

The system, which includes Dynamic Edge Gating Technology, utilizes miniature implanted transponders to provide information on the location of the tumor during external beam radiation therapy and may decrease in the side effects associated with prostate radiotherapy, stated the Seattle-based company.